Continuous Venovenous Hemodiafiltration Versus Sustained Low-efficiency Hemodialysis for Critically Ill Patients With Acute Kidney Injury in Intensive Care Unit
- Conditions
- Acute Kidney Injury
- Interventions
- Procedure: Slow efficiency dialysis
- Registration Number
- NCT02879201
- Brief Summary
The investigators conducted a comparison trial between SLED and CRRT in critically ill patients to evaluate the outcome for all cause mortality at 30 day . The secondary outcome were recovery of renal function, complications during therapy and duration of hospitalization.
- Detailed Description
The investigators performed a single center experience accumulated over 12 months since February 2009 with a continuous venovenous hemodiafiltration (CVVHDF) and hybrid technique named sustained low-efficiency dialysis (SLED). The primary end point was death from any cause by day 30. Intensive care unit (ICU) patients were eligible for inclusion when serum creatinine was \> 2 mg/dL, and renal replacement therapy (RRT) was initiated. The selected patients were treated with CVVHDF or SLED.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 27
- The inclusion criteria were
- AKI requiring RRT
- Hemodynamic instability defined by systolic blood pressure ≤ 90 mmHg and/or diastolic blood pressure ≤ 60 mmHg
- Patients requiring initiation to vasopressor support
- Patients with pre-existing chronic kidney disease ( eGFR less than 30 mLmin/1.73m2) were excluded
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Slow efficiency dialysis Slow efficiency dialysis SLED is a kind of hemodialysis technique performed using Fresenius 4008B dialysis machine with FDX 120 GW (NIKKISO Japan) dialyzer. SLED sessions were 6-8 hour duration, three times per week (except Sunday), In case of severe volume overload, the session could be increased to meet clinical situation. Blood flow was maintained between 150-200 mL/hr and the dialysate flow of 300 mL/hr. Both the groups use unfractionated heparin as anticoagulant to prevent clotting of the extracorporeal circuit .the target partial thromboplastin time( PTT) was not more than twice the control level.
- Primary Outcome Measures
Name Time Method All-cause mortality 30 day ll-cause mortality at 30 days following RRT initiation
- Secondary Outcome Measures
Name Time Method ICU stay 30 days Total days in ICU
Numbers of patients with abnormal laboratory values 30 days Renal function impairment
Trial Locations
- Locations (1)
Renal Unit, BMA Medical College and Vajira Hospital
🇹🇭Bangkok, Thailand